Skip to main content

Kraken Robotics Announces Signing of Strategic Acquisition to Expand Global Maritime Capabilities

$615 Million Acquisition of the Covelya Group Will Be Partially Financed Through a $350 Million Public Offering of Subscription Receipts Preliminary 2025 Year-End Results and Stand-Alone 2026 Guidance Provided for Kraken Robotics THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES THE BASE SHELF PROSPECTUS IS ACCESSIBLE, AND THE SHELF PROSPECTUS SUPPLEMENT FOR THE PUBLIC OFFERING AND ANY AMENDMENT TO THE DOCUMENTS WILL BE ACCESSIBLE, WITHIN TWO BUSINESS DAYS, THROUGH SEDAR+ (All dollar amounts are expressed in Canadian dollars, unless otherwise noted.) ST. JOHN’S, Newfoundland, March 03, 2026 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG), is pleased to announce that it has entered into an agreement to acquire Covelya Group Limited (“Covelya...

Continue reading

Dave Announces Proposed Offering of Convertible Notes

Company plans to enter into capped call transactions and repurchase shares of its common stock to opportunistically create value for shareholders Los Angeles, March 03, 2026 (GLOBE NEWSWIRE) — Dave Announces Proposed Offering of Convertible Notes Company plans to enter into capped call transactions and repurchase shares of its common stock to opportunistically create value for shareholders LOS ANGELES, CA – March 3, 2026 – Dave Inc. (NASDAQ: DAVE) (“Dave” or the “Company”) today announced that it plans to offer, subject to market and other conditions, $150 million principal amount of its Convertible Senior Notes due 2031 (the “notes”) through a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Dave expects...

Continue reading

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonist GSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rate Expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys at GSK’s peak sales guidance of >$2.7 billion as early as 2029 Year-end 2025 cash and investments of ~$311 millionSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided...

Continue reading

Fuel Tech Reports 2025 Fourth Quarter and Full Year Financial Results

WARRENVILLE, Ill., March 03, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of achievement for Fuel Tech, highlighted by a resurgence at our FUEL CHEM® operations that produced the highest annual segment revenue since 2018, a broadened opportunity landscape at our Air Pollution Control (“APC”) business segment driven in large part by the expected growth of power generation to support data center construction and operation, and measurable progress at our Dissolved Gas Infusion (“DGI”) business segment,” said Vincent J. Arnone, President and CEO....

Continue reading

Latham Group Acquires Freedom Pools

Combination Creates a Market-Leader in Fiberglass Pools Across Australia and New Zealand Transaction Expected to be Immediately Accretive to EarningsLATHAM, N.Y., March 03, 2026 (GLOBE NEWSWIRE) — Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it has acquired Freedom Pools, a fiberglass pool manufacturer and installer operating in Australia and New Zealand. The transaction was completed on February 26, 2026. The acquisition is expected to be immediately accretive to Latham’s earnings, adding approximately $20 million in net sales and approximately $4 million in adjusted EBITDA, on an annualized basis, before acquisition synergies. The purchase price was approximately $17 million, and...

Continue reading

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029ZUG, Switzerland, March 3, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology,...

Continue reading

Black Rock Coffee Bar, Inc. Reports Fourth Quarter and Full Year 2025 Results

Total Revenue Growth of 25.3% Year Over Year in the Fourth Quarter Same Store Sales Growth of 9.3% Year Over Year in the Fourth Quarter Opened 12 New Stores in the Fourth Quarter SCOTTSDALE, Ariz., March 03, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (Nasdaq: BRCB) (“Black Rock Coffee Bar” or the “Company”) today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter 2025 HighlightsOpened 12 new stores during the period Total revenue of $53.6 million, up 25.3% compared to the prior year period Same Store Sales Growth(1) increased 9.3% compared to the prior year period Income (loss) from operations of $1.8 million compared to $(0.1) million in the prior year period. In the fourth quarter of 2025, income from operations margin was 3.3% Store-Level Profit(2) of $15.7 million as compared...

Continue reading

Cricut, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Delivered 9th consecutive year of profitability with net income of $76.7 million, or 10.8% margin Net Income increased 22%, or $13.9 million, compared to 2024 Generated $200 million in Cash from Operations in 2025 Paid subscribers increased over 4% to just over 3.09 million, compared to 2024  2025 revenue of $708.8 million, a less than 1% decline compared to 2024 SOUTH JORDAN, Utah, March 03, 2026 (GLOBE NEWSWIRE) — Cricut, Inc. (“Cricut”) (NASDAQ: CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced financial results for its fourth quarter and full year ended December 31, 2025. “While we are pleased with increased profitability with net income up 22%, the over 4% increase in paid subscribers, and positive machine-sell out units in both North...

Continue reading

Superior Group of Companies Reports Fourth Quarter 2025 Results

– Total net sales of $146.6 million versus $145.4 million in prior year fourth quarter –– Net income of $3.5 million versus $2.1 million in prior year fourth quarter –– EBITDA of $8.6 million versus $7.3 million in prior year fourth quarter –– Provides full-year outlook – ST. PETERSBURG, Fla., March 03, 2026 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its fourth quarter 2025 results. “We finished the year with a solid fourth quarter, growing our consolidated revenues while simultaneously reducing expenses which resulted in 19% year-over-year EBITDA growth and earnings per share that nearly doubled,” said Michael Benstock, Chief Executive Officer.  “In addition, our quarterly results again demonstrated the back-end weighted nature of our business, with 6% sequential...

Continue reading

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived therapy, as a one-time treatment for patients with type 1 diabetes, with a goal of normal blood glucose, with no insulin and no immunosuppression Made significant progress with SC451 across manufacturing, regulatory, and clinical trial preparedness, including the non-clinical testing plan and manufacture of the master cell bank Expect to file investigational...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.